Ind-Swift Limited is a manufacturer of formulations. The Company operates through pharmaceutical products segment. Its geographic segments include domestic and export. The Company has a portfolio of over 750 products in therapeutic segments, such as cardiology, diabetology, anti-depressant, anti-allergic, anti-infective, neurology, oncology and dermatology. Its portfolio of active pharmaceutical ingredients (APIs) in pipeline include Fluvastatin; Risedronate; Ezetimibe; Acamprosate; Montelukast Na; Cinacalcet; Duloxetine and Naratriptan HCl. The Company operates through divisions, including Megaswift division, which offers chest (anti- tuberculosis); dentistry; anti-infective; cardio-diabetic and orthopedic products; Gyno Swift division, which produces a range of gynecology and dermatology products, such as Suprox SR and Voranin and Malswift-D; Generic division, which includes Agile, Maxcare and Healthcare divisions, and Institutional division, which caters to government dispensaries.